Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer.

Wagner J, Rapsomaniki MA, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, Rees M, Ramaswamy A, Muenst S, Soysal SD, Jacobs A, Windhager J, Silina K, van den Broek M, Dedes KJ, Rodríguez Martínez M, Weber WP, Bodenmiller B.

Cell. 2019 May 16;177(5):1330-1345.e18. doi: 10.1016/j.cell.2019.03.005. Epub 2019 Apr 11.

2.

Breast Cancer Assessment With Pulse-Echo Speed of Sound Ultrasound From Intrinsic Tissue Reflections: Proof-of-Concept.

Ruby L, Sanabria SJ, Martini K, Dedes KJ, Vorburger D, Oezkan E, Frauenfelder T, Goksel O, Rominger MB.

Invest Radiol. 2019 Jul;54(7):419-427. doi: 10.1097/RLI.0000000000000553.

PMID:
30913054
3.

Cost-effectiveness of nivolumab in the treatment of head and neck cancer.

Hirschmann A, Lupatsch JE, Schwenkglenks M, Panje CM, Matter-Walstra K, Espeli V, Dedes KJ, Siano M; Swiss Group of Clinical Cancer Research (SAKK).

Oral Oncol. 2018 Dec;87:104-110. doi: 10.1016/j.oraloncology.2018.10.032. Epub 2018 Oct 30.

PMID:
30527224
4.

A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).

Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK).

Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017. Epub 2018 Aug 10.

PMID:
30104008
5.

Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial.

Weber WP, Tausch C, Hayoz S, Fehr MK, Ribi K, Hawle H, Lupatsch JE, Matter-Walstra K, Chiesa F, Dedes KJ, Berclaz G, Lelièvre L, Hess T, Güth U, Pioch V, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal SD, Ruhstaller T, Fehr PM, Knauer M; Swiss Group for Clinical Cancer Research (SAKK).

Ann Surg Oncol. 2018 Sep;25(9):2632-2640. doi: 10.1245/s10434-018-6556-9. Epub 2018 Jun 8.

PMID:
29948418
6.

Feasibility of 18F-FDG Dose Reductions in Breast Cancer PET/MRI.

Sah BR, Ghafoor S, Burger IA, Ter Voert EEGW, Sekine T, Delso G, Huellner M, Dedes KJ, Boss A, Veit-Haibach P.

J Nucl Med. 2018 Dec;59(12):1817-1822. doi: 10.2967/jnumed.118.209007. Epub 2018 Jun 7.

PMID:
29880506
7.

Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients.

Stämpfli SF, Akhmedov A, Hausladen S, Varga Z, Dedes KJ, Hellermann J, Lüscher TF, Kristiansen G, Tanner FC, Breitenstein A.

Anticancer Res. 2017 Jun;37(6):3259-3264.

PMID:
28551673
8.

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).

Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1.

9.

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.

Matter-Walstra K, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2017 Jun;163(3):635. doi: 10.1007/s10549-017-4209-5. Epub 2017 Mar 21. No abstract available.

PMID:
28321586
10.

First ultrasound diagnosis of BI-RADS 3 lesions in young patients: Can 6-months follow-up be sufficient to assess stability?

Marcon M, Frauenfelder T, Becker AS, Dedes KJ, Boss A.

Eur J Radiol. 2017 Apr;89:226-233. doi: 10.1016/j.ejrad.2017.02.012. Epub 2017 Feb 16.

PMID:
28267544
11.

Uterine Tumors Resembling Ovarian Sex Cord Tumors - Treatment, recurrence, pregnancy and brief review.

Schraag SM, Caduff R, Dedes KJ, Fink D, Schmidt AM.

Gynecol Oncol Rep. 2017 Jan 11;19:53-56. doi: 10.1016/j.gore.2017.01.004. eCollection 2017 Feb.

12.

A Micro CT Study in Patients with Breast Microcalcifications Using a Mathematical Algorithm to Assess 3D Structure.

Kenkel D, Varga Z, Heuer H, Dedes KJ, Berger N, Filli L, Boss A.

PLoS One. 2017 Jan 20;12(1):e0169349. doi: 10.1371/journal.pone.0169349. eCollection 2017.

13.

Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.

Valtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt AM, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes KJ, Wild PJ.

BMC Cancer. 2017 Jan 19;17(1):66. doi: 10.1186/s12885-017-3054-6.

14.

Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.

Brandt S, Samartzis EP, Zimmermann AK, Fink D, Moch H, Noske A, Dedes KJ.

BMC Cancer. 2017 Jan 10;17(1):44. doi: 10.1186/s12885-016-3026-2.

15.

Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.

Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS.

Oncotarget. 2017 Jan 24;8(4):6057-6066. doi: 10.18632/oncotarget.14011.

16.

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2016 Jul;158(1):51-57. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8.

PMID:
27277747
17.

Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report.

Hempen A, Samartzis EP, Kamarachev J, Fink D, Dedes KJ.

BMC Cancer. 2015 Jul 8;15:507. doi: 10.1186/s12885-015-1527-z.

18.

Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.

Ihnenfeld Arciénega I, Imesch P, Fink D, Dedes KJ.

Target Oncol. 2015 Jun;10(2):297-301. doi: 10.1007/s11523-014-0350-9. Epub 2014 Dec 17. Review.

19.

Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.

Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P.

Oncotarget. 2014 Jul 30;5(14):5295-303.

20.

Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.

Koppensteiner R, Samartzis EP, Noske A, von Teichman A, Dedes I, Gwerder M, Imesch P, Ikenberg K, Moch H, Fink D, Stucki M, Dedes KJ.

PLoS One. 2014 Jun 13;9(6):e100041. doi: 10.1371/journal.pone.0100041. eCollection 2014.

21.

Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.

Natrajan R, Wilkerson PM, Marchiò C, Piscuoglio S, Ng CK, Wai P, Lambros MB, Samartzis EP, Dedes KJ, Frankum J, Bajrami I, Kopec A, Mackay A, A'hern R, Fenwick K, Kozarewa I, Hakas J, Mitsopoulos C, Hardisson D, Lord CJ, Kumar-Sinha C, Ashworth A, Weigelt B, Sapino A, Chinnaiyan AM, Maher CA, Reis-Filho JS.

J Pathol. 2014 Apr;232(5):553-65. doi: 10.1002/path.4325. Epub 2014 Feb 5.

22.

ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.

Samartzis EP, Noske A, Dedes KJ, Fink D, Imesch P.

Int J Mol Sci. 2013 Sep 12;14(9):18824-49. doi: 10.3390/ijms140918824. Review.

23.

Histone deacetylase inhibitors down-regulate G-protein-coupled estrogen receptor and the GPER-antagonist G-15 inhibits proliferation in endometriotic cells.

Imesch P, Samartzis EP, Dedes KJ, Fink D, Fedier A.

Fertil Steril. 2013 Sep;100(3):770-6. doi: 10.1016/j.fertnstert.2013.05.008. Epub 2013 Jun 10.

PMID:
23755949
24.

Bilateral transient osteoporosis of the knee during pregnancy.

Charpidou T, Lang F, Langenegger T, Dedes KJ, Honegger C.

Arch Gynecol Obstet. 2013 Jun;287(6):1259-61. doi: 10.1007/s00404-012-2628-4. Epub 2012 Nov 21. No abstract available.

PMID:
23179799
25.

Expression of the G protein-coupled estrogen receptor (GPER) in endometriosis: a tissue microarray study.

Samartzis N, Samartzis EP, Noske A, Fedier A, Dedes KJ, Caduff R, Fink D, Imesch P.

Reprod Biol Endocrinol. 2012 Apr 20;10:30. doi: 10.1186/1477-7827-10-30.

26.

Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?

Samartzis EP, Samartzis N, Noske A, Fedier A, Caduff R, Dedes KJ, Fink D, Imesch P.

Mod Pathol. 2012 Jun;25(6):885-92. doi: 10.1038/modpathol.2011.217. Epub 2012 Feb 3.

27.

Inpatient and outpatient loop electrosurgery excision procedure for cervical intraepithelial neoplasia: a retrospective analysis.

Leimbacher B, Samartzis N, Imesch P, Dedes KJ, Fink D, Canonica C.

Arch Gynecol Obstet. 2012 May;285(5):1441-5. doi: 10.1007/s00404-011-2148-7. Epub 2011 Nov 25.

PMID:
22116315
28.

Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study.

Samartzis N, Imesch P, Dedes KJ, Samartzis EP, Fedier A, Fink D, Caduff R, Fehr MK.

BMC Cancer. 2011 Oct 26;11:463. doi: 10.1186/1471-2407-11-463.

29.

Functional viability profiles of breast cancer.

Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, Costa-Cabral S, Rafiq R, Ahmad AS, Cerone MA, Natrajan R, Sharpe R, Shiu KK, Wetterskog D, Dedes KJ, Lambros MB, Rawjee T, Linardopoulos S, Reis-Filho JS, Turner NC, Lord CJ, Ashworth A.

Cancer Discov. 2011 Aug;1(3):260-73. doi: 10.1158/2159-8290.CD-11-0107. Epub 2011 Aug 2.

30.

Revisiting the role of antiandrogen strategies in ovarian cancer.

Papadatos-Pastos D, Dedes KJ, de Bono JS, Kaye SB.

Oncologist. 2011;16(10):1413-21. doi: 10.1634/theoncologist.2011-0164. Epub 2011 Sep 23. Review.

31.

Non-existence of caveolin-1 gene mutations in human breast cancer.

Patani N, Lambros MB, Natrajan R, Dedes KJ, Geyer FC, Ward E, Martin LA, Dowsett M, Reis-Filho JS.

Breast Cancer Res Treat. 2012 Jan;131(1):307-10. doi: 10.1007/s10549-011-1761-2. Epub 2011 Sep 11.

PMID:
21909981
32.

Functional characterization of EMSY gene amplification in human cancers.

Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS.

J Pathol. 2011 Sep;225(1):29-42. doi: 10.1002/path.2944. Epub 2011 Jul 7.

PMID:
21735447
33.

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.

Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS.

Cell Cycle. 2011 Apr 15;10(8):1192-9. Epub 2011 Apr 15.

34.

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB, Molife LR.

Nat Rev Clin Oncol. 2011 May;8(5):302-6. doi: 10.1038/nrclinonc.2011.42. Epub 2011 Apr 5.

PMID:
21468130
35.

Emerging therapeutic targets in endometrial cancer.

Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS.

Nat Rev Clin Oncol. 2011 May;8(5):261-71. doi: 10.1038/nrclinonc.2010.216. Epub 2011 Jan 11. Review.

PMID:
21221135
36.

PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, Ashworth A, Reis-Filho JS.

Sci Transl Med. 2010 Oct 13;2(53):53ra75. doi: 10.1126/scitranslmed.3001538.

37.

Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer.

Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, Jones RL, Reis-Filho JS.

Eur J Cancer. 2011 Jan;47(1):138-50. doi: 10.1016/j.ejca.2010.08.007. Epub 2010 Sep 9.

PMID:
20832293
38.

PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.

Lambros MB, Natrajan R, Geyer FC, Lopez-Garcia MA, Dedes KJ, Savage K, Lacroix-Triki M, Jones RL, Lord CJ, Linardopoulos S, Ashworth A, Reis-Filho JS.

Mod Pathol. 2010 Oct;23(10):1334-45. doi: 10.1038/modpathol.2010.121. Epub 2010 Jun 11.

39.

Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.

Blank PR, Dedes KJ, Szucs TD.

Pharmacoeconomics. 2010;28(8):629-47. doi: 10.2165/11535560-000000000-00000. Review.

PMID:
20524722
40.

Trastuzumab beyond progression: a cost-utility analysis.

Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC.

Ann Oncol. 2010 Nov;21(11):2161-8. doi: 10.1093/annonc/mdq250. Epub 2010 May 5.

41.

Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study.

Dedes KJ, Lopez-Garcia MA, Geyer FC, Lambros MB, Savage K, Vatcheva R, Wilkerson P, Wetterskog D, Lacroix-Triki M, Natrajan R, Reis-Filho JS.

Breast Cancer Res Treat. 2010 Dec;124(3):653-66. doi: 10.1007/s10549-010-0816-0. Epub 2010 Mar 6.

PMID:
20213079
42.

Clinical presentation and surgical management of invasive lobular carcinoma of the breast.

Dedes KJ, Fink D.

Breast Dis. 2008-2009;30:31-7. doi: 10.3233/BD-2009-0277. Review.

PMID:
19850993
43.

MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.

Imesch P, Dedes KJ, Furlato M, Fink D, Fedier A.

Int J Oncol. 2009 Sep;35(3):631-40.

44.
45.

Is cancer prevention ever going to be profitable?

Szucs TD, Dedes KJ.

Recent Results Cancer Res. 2009;181:41-7. Review.

PMID:
19213555
46.

Outcome of treated anogenital intraepithelial neoplasia among human immunodeficiency virus-infected women.

Dedes KJ, Beneder C, Samartzis N, Muller MD, Fink D, Fehr MK.

J Reprod Med. 2008 Dec;53(12):947-51.

PMID:
19160654
47.

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.

Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, Szucs TD.

Eur J Cancer. 2009 May;45(8):1397-406. doi: 10.1016/j.ejca.2008.12.016. Epub 2009 Jan 13.

PMID:
19147344
48.

Balancing costs and benefits in cancer therapy and prevention.

Szucs TD, Dedes KJ.

Ann Oncol. 2008 Sep;19 Suppl 7:vii313-9. doi: 10.1093/annonc/mdn475. No abstract available.

49.

[Current adjuvant endocrine treatment of breast cancer].

Dedes KJ, Gabriel N, Fink D.

Gynakol Geburtshilfliche Rundsch. 2008;48(3):130-7. doi: 10.1159/000127394. Epub 2008 Jun 17. Review. German.

PMID:
18566529
50.

Impact of clinical pathways in surgery.

Müller MK, Dedes KJ, Dindo D, Steiner S, Hahnloser D, Clavien PA.

Langenbecks Arch Surg. 2009 Jan;394(1):31-9. doi: 10.1007/s00423-008-0352-0. Epub 2008 Jun 3.

PMID:
18521624

Supplemental Content

Loading ...
Support Center